JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

Search

Boston Scientific Corp.

Geschlossen

BrancheGesundheitswesen

100.99 -1.37

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

100.89

Max

102.83

Schlüsselkennzahlen

By Trading Economics

Einkommen

123M

795M

Verkäufe

398M

5.1B

KGV

Branchendurchschnitt

59.135

37.461

Gewinnspanne

15.708

Angestellte

53,000

EBITDA

155M

1.4B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+25.24% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-4.6B

149B

Vorheriger Eröffnungskurs

102.36

Vorheriger Schlusskurs

100.99

Nachrichtenstimmung

By Acuity

24%

76%

47 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Boston Scientific Corp. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Okt. 2025, 11:00 UTC

Ergebnisse

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

17. Okt. 2025, 11:43 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

23. Juli 2025, 11:16 UTC

Ergebnisse

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

22. Okt. 2025, 10:32 UTC

Ergebnisse

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22. Okt. 2025, 10:32 UTC

Ergebnisse

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22. Okt. 2025, 10:31 UTC

Ergebnisse

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22. Okt. 2025, 10:31 UTC

Ergebnisse

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 3Q Adj EPS 75c >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 3Q Sales $5.07B >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific 3Q EPS 51c >BSX

22. Okt. 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

17. Okt. 2025, 11:02 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

17. Okt. 2025, 11:02 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

17. Okt. 2025, 11:01 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

17. Okt. 2025, 11:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

9. Sept. 2025, 12:58 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9. Sept. 2025, 12:31 UTC

Akquisitionen, Fusionen, Übernahmen

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23. Juli 2025, 10:32 UTC

Ergebnisse

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23. Juli 2025, 10:31 UTC

Ergebnisse

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23. Juli 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23. Juli 2025, 10:30 UTC

Ergebnisse

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23. Juli 2025, 10:30 UTC

Ergebnisse

Boston Scientific 2Q EPS 53c >BSX

23. Juli 2025, 10:30 UTC

Ergebnisse

Boston Scientific 2Q Sales $5.06B >BSX

23. Juli 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23. Juli 2025, 10:30 UTC

Ergebnisse

Boston Scientific 2Q Adj EPS 75c >BSX

23. Juli 2025, 10:30 UTC

Ergebnisse

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Peer-Vergleich

Kursveränderung

Boston Scientific Corp. Prognose

Kursziel

By TipRanks

25.24% Vorteil

12-Monats-Prognose

Durchschnitt 126.45 USD  25.24%

Hoch 140 USD

Tief 113 USD

Basierend auf 24 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Boston Scientific Corp. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

24 ratings

23

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

102.95 / 104.93Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

47 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat